Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Internal Medicine Journal|May 27, 2015
Ipilimumab-induced hypophysitis in melanoma patients: an Australian case seriesT Lam, M M K Chan, A N Sweeting, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2016
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 studyG V Long, V Atkinson, P A Ascierto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanomaJ H Lee, G V Long, S Boyd, et al.
Oncoimmunology|October 21, 2016
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanomaE Liniker, A M Menzies, B Y Kong, et al.
ESMO Open|May 26, 2026
Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02CM Tetzlaff, J M Taube, G V Long, et al.
British Journal of Cancer|June 12, 2014
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanomaM S Carlino, L E Haydu, H Kakavand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2019
Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patientsJ H Lee, R P Saw, J F Thompson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 13, 2023
Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanomaB Lian, Z Li, N Wu, et al.
British Journal of Cancer|April 29, 2016
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyS Bowyer, P Prithviraj, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2024
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 studyG V Long, M S Carlino, C McNeil, et al.
Pageof 6